Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

被引：20

作者：

Bendell, Johanna C. ^{[1
]}

Bedard, Philippe ^{[2
]}

Bang, Yung-Jue ^{[3
]}

LoRusso, Patricia ^{[4
]}

Hodi, Stephen ^{[5
]}

Gordon, Michael ^{[6
]}

D'Angelo, Sandra ^{[7
]}

Desai, Jayesh ^{[8
]}

Garralda, Elena ^{[9
]}

Italiano, Antoine ^{[10
]}

Myung-Ju Ahn ^{[11
]}

Cervantes, Andres ^{[12
]}

Wainberg, Zev ^{[13
]}

Calvo, Emiliano ^{[14
]}

Gil-Martin, Marta ^{[15
]}

Martinez-Garcia, Maria ^{[16
]}

Bahleda, Rastilav ^{[17
]}

Cassier, Philippe ^{[18
]}

Delord, Jean-Pierre ^{[19
]}

Prawira, Amy ^{[20
]}

Melero, Ignacio ^{[21
]}

Emens, Leisha ^{[22
]}

Romano, Emanuela ^{[23
]}

Miller, Karen ^{[24
]}

Hsieh, Robert W. ^{[25
]}

Xue, Cloris ^{[24
]}

Morrissey, Kari ^{[24
]}

Twomey, Patrick ^{[24
]}

Gash, Kelly ^{[24
]}

Patil, Namrata S. ^{[24
]}

Grogan, Jane ^{[24
]}

Meng, Raymond ^{[24
]}

Cho, Byoung ^{[26
]}

Kim, Tae Won ^{[27
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Princess Margaret Hosp, Toronto, ON, Canada

[3] Seoul Natl Univ Hosp, Seoul, South Korea

[4] Yale Canc Ctr, New Haven, CT USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] HonorHlth Res Inst, Scottsdale, AZ USA

[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[9] Hosp Univ Vall dHebron, Barcelona, Spain

[10] Inst Bergonie CLCC, Bordeaux, France

[11] Samsung Med Ctr, Seoul, South Korea

[12] Hosp Clin Univ Valencia, Valencia, Spain

[13] Univ Calif Los Angeles, Los Angeles, CA USA

[14] Hosp Univ HM Sanchinarro CIOCC, Madrid, Spain

[15] ICO Hosp, Barcelona, Spain

[16] Hosp del Mar, Barcelona, Spain

[17] Inst Gustave Roussy, Villejuif, France

[18] Ctr Leon Berard Ctr Reg Lutte Canc Rhone Alpes, Lyon, France

[19] Inst Claudius Regaud, Toulouse, France

[20] St Vincents Hosp, Darlinghurst, NSW, Australia

[21] Clin Univ Navarra, Navarra, Spain

[22] Johns Hopkins Univ, Baltimore, MD USA

[23] Inst Curie, Paris, France

[24] Genentech Inc, San Francisco, CA 94080 USA

[25] F Hoffmann La Roche, Mississauga, ON, Canada

[26] Sarah Cannon Res Inst, Seoul, South Korea

[27] Asan Med Ctr, Seoul, South Korea

来源：

CANCER RESEARCH | 2020年 / 80卷 / 16期

关键词：

D O I：

10.1158/1538-7445.AM2020-CT302

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT302

引用

页数：3

共 50 条

[21] Phase Ia/Ib dose-escalation study of ABL001 (CTX-009, bispecific antibody targeting DLL4 and VEGF-A) as a single agent in patients with advanced solid tumors
Lee, Jeeyun
Kim, SeungTae
Hong, JungYong
Park, YoungSuk
Park, JoonOh
Kang, Wonki
Lee, Keun-Wook
Kim, Jin Won
Kim, Ji-Won
Kim, Se Hyun
Ha, Eunsin
Lee, Sangmi
Kim, JongRan
You, Weon-Kyoo
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[22] A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors.
Yamamoto, Noboru
Hafez, Navid
Tolcher, Anthony W.
Teufel, Michael
Geng, Junxian
Svensson, Liz
Lahmar, Mehdi
Gounder, Mrinal M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[23] Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors
Lorusso, D.
Fornari, G.
Caponigro, F.
Quirino, M.
Merlano, M.
Airoldi, M.
Schena, M.
Jannuzzo, M. G.
Crippa, S.
Scambia, G.
EJC SUPPLEMENTS, 2007, 5 (04): : 111 - 112
[24] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
A. Craig Lockhart
Shankar Sundaram
John Sarantopoulos
Monica M. Mita
Andrea Wang-Gillam
Jennifer L. Moseley
Stephanie L. Barber
Alex R. Lane
Claudine Wack
Laurent Kassalow
Jean-François Dedieu
Alain C. Mita
Investigational New Drugs, 2014, 32 : 1236 - 1245
[25] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
Jeffrey R. Infante
Roger B. Cohen
Kevin B. Kim
Howard A. Burris
Gregory Curt
Ugochi Emeribe
Delyth Clemett
Helen K. Tomkinson
Patricia M. LoRusso
Investigational New Drugs, 2017, 35 : 576 - 588
[26] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
Lockhart, A. Craig
Sundaram, Shankar
Sarantopoulos, John
Mita, Monica M.
Wang-Gillam, Andrea
Moseley, Jennifer L.
Barber, Stephanie L.
Lane, Alex R.
Wack, Claudine
Kassalow, Laurent
Dedieu, Jean-Francois
Mita, Alain C.
INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1236 - 1245
[27] Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
Isambert, Nicolas
Freyer, Gilles
Zanetta, Sylvie
You, Benoit
Fumoleau, Pierre
Falandry, Claire
Favier, Laure
Assadourian, Sylvie
Soussan-Lazard, Karen
Ziti-Ljajic, Samira
Trillet-Lenoir, Veronique
CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1743 - 1750
[28] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
Infante, Jeffrey R.
Cohen, Roger B.
Kim, Kevin B.
Burris, Howard A., III
Curt, Gregory
Emeribe, Ugochi
Clemett, Delyth
Tomkinson, Helen K.
LoRusso, Patricia M.
INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 576 - 588
[29] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
LoRusso, Patricia M.
Infante, Jeffrey R.
Kim, Kevin B.
Burris, Howard A., III
Curt, Gregory
Emeribe, Ugochi
Clemett, Delyth
Tomkinson, Helen K.
Cohen, Roger B.
BMC CANCER, 2017, 17
[30] A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with docetaxel in patients with advanced solid tumors
Robert, F.
Sandler, A.
Schiller, J. H.
Ilagan, J.
Harper, K.
Vermeulen, W.
Liu, G.
Tye, L.
Chao, R.
Verkh, L.
Traynor, A.
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3514S - 3515S

← 1 2 3 4 5 →